The lab test used by doctors for checking the protein programmed cell death ligand 1 (PD-L1) in tumor tissue obtained from patients, who have esophageal squamous cell cancer is done by PD-L1 IHC 22C3 pharmDx. This test has recently got the approval from the USFDA.
The small piece of cancerous tissue from the patient is sent to a lab. The lab then puts the cancerous tissue into wax and cuts a thin slice of it. And then, it is treated with the test slice. If the slice has PD-L1, it will stain dark brown. The pathologist looks at the slice. The lab tells the doctor whether PD-L1 was present in the slice or not. It will help in the determination of the sample positivity based on criteria that are specific for each cancer type.
PD-L1 IHC 22C3 pharmDx can be used by doctors to help in evaluating whether a patient is eligible for treatment with KEYTRUDA®.
There are no known contraindications linked with this testing.
Copyright © 2019 Institute of Good Manufacturing Practices India ( IGMPI® All Rights Reserved. Trademarks are the property of the owner )